These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3461888)

  • 21. Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.
    Pratt CB; Crom DB; Wallenberg J; Sanyal SK; Miliauskas J; Sohlberg K
    Cancer Treat Rep; 1983 Jan; 67(1):85-8. PubMed ID: 6684503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitoxantrone: a new anticancer drug with significant clinical activity.
    Shenkenberg TD; Von Hoff DD
    Ann Intern Med; 1986 Jul; 105(1):67-81. PubMed ID: 3521429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
    Delozier T; Vernhes JC
    Bull Cancer; 1991 Nov; 78(11):1013-25. PubMed ID: 1369547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.
    Saletan S
    Cancer Treat Rev; 1987 Dec; 14(3-4):297-303. PubMed ID: 3326667
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats.
    Zbinden G; Beilstein AK
    Toxicol Lett; 1982 May; 11(3-4):289-97. PubMed ID: 7101322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
    Rozencweig M; ten Bokkel Huinink W; Cavalli F; Bruntsch U; Dombernowsky P; Høst H; Bramwell V; Renard G; Van Glabbeke M; Decoster G
    J Clin Oncol; 1984 Apr; 2(4):275-81. PubMed ID: 6584561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone.
    Villani F; Galimberti M; Crippa F
    Drugs Exp Clin Res; 1989; 15(10):501-6. PubMed ID: 2632218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
    Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
    J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones.
    Buschini A; Poli P; Rossi C
    Mutagenesis; 2003 Jan; 18(1):25-36. PubMed ID: 12473732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
    Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
    Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
    Lechner W; Reider W; Hetzel H; Daxenbichler G; Marth C
    Gynecol Obstet Invest; 1986; 22(1):42-6. PubMed ID: 3462098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
    De Leonardis V; De Scalzi M; Neri B; Bartalucci S; Cinelli P
    Int J Clin Pharmacol Res; 1987; 7(4):307-11. PubMed ID: 3474215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiotoxicity associated with mitoxantrone.
    Stuart-Harris R; Pearson M; Smith IE; Olsen EG
    Lancet; 1984 Jul; 2(8396):219-20. PubMed ID: 6146768
    [No Abstract]   [Full Text] [Related]  

  • 35. Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone.
    Crescimanno M; Flandina C; Rausa L; Sanguedolce R; D'Alessandro N
    Chemioterapia; 1988 Feb; 7(1):53-9. PubMed ID: 3163942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line mitoxantrone chemotherapy for advanced breast cancer.
    Wilson KS; Paterson AH
    Cancer Treat Rep; 1986 Aug; 70(8):1021-2. PubMed ID: 3731148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
    Bull FE; Von Hoff DD; Balcerzak SP; Stephens RL; Panettiere FJ
    Cancer Treat Rep; 1985 Feb; 69(2):231-3. PubMed ID: 3882233
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Contribution of electron microscopy to the study of anthracycline cardiotoxicity].
    Anjo A; Levi F; Reynes M
    Bull Assoc Anat (Nancy); 1991 Jun; 75(229):7-9. PubMed ID: 1777720
    [No Abstract]   [Full Text] [Related]  

  • 40. Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent.
    Bertazzoli C; Rovero C; Ballerini L; Lux B; Balconi F; Antongiovanni V; Magrini U
    Toxicol Appl Pharmacol; 1985 Jul; 79(3):412-22. PubMed ID: 3862266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.